keyword
MENU ▼
Read by QxMD icon Read
search

Intravesical therapy

keyword
https://www.readbyqxmd.com/read/28516158/a-management-algorithm-for-mitomycin-c-induced-cystitis
#1
Amy N Luckenbaugh, Rory M Marks, David C Miller, Alon Z Weizer, John T Stoffel, Jeffrey S Montgomery
Background/Objective: A post-bladder tumor resection dose of MMC can reduce non-invasive papillary (pTa) bladder cancer recurrences by up to 40%; this treatment is recommended in both the AUA and EUA non-muscle-invasive bladder cancer guidelines. A common complication of this treatment is eosinophilic cystitis. Symptoms range from mild urinary frequency and urgency to debilitating pain and dysuria. Currently, there is no established treatment algorithm for MMC-induced cystitis. Methods: Members of the Urologic Surgery Quality Collaborative (USQC), a group composed of over 160 private and academic urologists, met to discuss the management of patients with cystitis following MMC therapy...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516156/single-arm-phase-i-ii-study-of-everolimus-and-intravesical-gemcitabine-in-patients-with-primary-or-secondary-carcinoma-in-situ-of-the-bladder-who-failed-bacillus-calmette-guerin-nct01259063
#2
Guido Dalbagni, Nicole Benfante, Daniel D Sjoberg, Bernard H Bochner, S Machele Donat, Harry W Herr, Asia S Mc Coy, Alicia J Fahrner, Caitlyn Retinger, Jonathan E Rosenberg, Dean F Bajorin
Background: Standard treatment for BCG-refractory urothelial cancer is radical cystectomy. Identification of active agents is clearly warranted. Objective: To determine a safe dose of oral everolimus in combination with standard intravesical gemcitabine and to evaluate the efficacy of this combination. Methods: Patients with carcinoma in situ refractory to intravesical bacillus Calmette-Guérin and refusing cystectomy were eligible. Patients in the phase I part of the trial received one of three dose levels of oral everolimus...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28505895/re-cytokine-panel-for-response-to-intravesical-therapy-cyprit-nomogram%C3%A2-of-changes-in-urinary-cytokine-levels-predicts-patient-response%C3%A2-to-bacillus-calmette-gu%C3%A3-rin
#3
https://www.readbyqxmd.com/read/28503891/the-use-of-intravesical-gentamicin-to-treat-recurrent-urinary-tract-infections-in-lower-urinary-tract-dysfunction
#4
Paul Abrams, Hashim Hashim, Charles Tomson, Alasdair Macgowan, Rachel Skews, Katherine Warren
AIMS: To assess the use of intravesical gentamicin to treat intractable recurrent urinary tract infections in lower urinary tract dysfunction. METHODS: A two-center retrospective cohort study of 27 patients treated with intravesical gentamicin was performed over a 2-year period. A treatment protocol was developed, reviewed, and accepted by the clinical effectiveness committee of both hospitals. Patients were taught to instill the gentamicin into the bladder on a nightly basis...
May 15, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28494780/metastatic-non-muscle-invasive-bladder-cancer-with-meningeal-carcinomatosis-case-report-of-an-unexpected-response
#5
Diego Teyssonneau, Amaury Daste, Vincent Dousset, Jean-Luc Hoepffner, Alain Ravaud, Marine Gross-Goupil
BACKGROUND: Non-muscle invasive bladder cancer (NMIBC) is usually treated with local therapy including transurethral resection of the bladder tumor and intravesical therapy depending on the stage of the tumor. NMIBC is a rarely a metastatic diseases with lymph node invasion in less of 10%. In the other hand meningeal carcinomatosis is a rare location for metastases with extremely poor outcomes. We described a case report of a patient presenting a metastatic disease to bones and meninges, several years after the treatment of NMIBC, which had been in complete response (CR) for 4 years after chemotherapy treatment...
May 11, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28480984/clinical-comparison-of-intravesical-hyaluronic-acid-and-chondroitin-sulfate-therapies-in-the-treatment-of-bladder-pain-syndrome-interstitial-cystitis
#6
Ömer Gülpınar, Barış Esen, Aytaç Kayış, Mehmet İlker Gökçe, Evren Süer
INTRODUCTION: Intravesical glucosaminoglycan (GAG) replacement therapies are commonly used in the treatment of bladder pain syndrome (BPS)/interstitial cystitis (IC). Different intravesical glucosaminoglycan products are currently available. In this prospective study, clinical efficacy of chondroitin sulfate and hyaluronic acid are compared in patients with BPS/IC. METHODS: Patients were randomized to CS and HA groups. All patients were evaluated for visual analogue pain scale (VAS), interstitial cystitis symptom index (ICSI), interstitial cystitis problem index (ICPI), voiding diary for frequency/nocturia, and mean urine volume per void at the beginning of the therapy and after 6 months...
May 8, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28471272/determining-the-optimal-maintenance-schedules-for-adjuvant-intravesical-bacillus-calmette-guerin-immunotherapy-in-non-muscle-invasive-bladder-cancer-a-systematic-review-and-network-meta-analysis
#7
Zixiong Huang, Huixin Liu, Yizeng Wang, Chunfang Zhang, Tao Xu
OBJECTIVES: To figure out optimal Bacillus Calmette-Guerin (BCG) maintenance schedules for non-muscle-invasive bladder cancer (NMIBC) patients by comparing different schedules in a systematic review using conventional and network meta-analysis. MATERIALS AND METHODS: Literature was searched in the databases of Medline, Embase, Cochrane library, Clinicaltrials.gov, Wanfang, CNKI and SinoMed in April2016 and 9 randomized clinical trials comparing intravesical BCG maintenance therapy with BCG induction-only therapy or comparing different BCG maintenance schedules (induction-only, 1-year, 1...
May 4, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28469275/prognostic-value-of-impaired-estimated-glomerular-filtration-rate-in-intravesical-bcg-treated-non-muscle-invasive-bladder-cancer-patients
#8
Bum Sik Tae, Jung Kwon Kim, Minyong Kang, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku
To evaluate the influence of patient-associated parameters and comorbities, with a special focus on renal function after intravesical adjuvant bacillus Calmette-Gue´rin (BCG) immunotherapy in patients with non-muscle-invasive bladder cancer (NMIBC). We retrospectively reviewed the medical records of patients treated from October, 1991 to December, 2013 at Seoul National University who were diagnosed with NMIBC and treated with intravesical BCG. A total of 344 patients who were diagnosed with NMIBC and treated with intravesical BCG were enrolled in this study...
May 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28467128/cystodistension-is-there-evidence-to-support-its-use-in-current-practice-for-patients-with-overactive-bladder
#9
Aswini Balachandran, Jonathan Duckett
Cystoscopy and cystodistension have been part of common treatment protocols for a variety of bladder conditions for many years. However, the science behind the procedure is not strong and continued use of the operation may not be justified. Much research is old and was not planned or executed with the current rigour demanded by current trial methods. Newer treatments such as intravesical botulinum toxin have been extensively researched and found to be effective. This review article aimed to review the evidence behind the use of cystodistension for overactive bladder (OAB) with the aim of identifying the weaknesses in the current evidence...
May 3, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28460622/intravesical-chemotherapy-and-chemohypherthermia-in-non-muscle-invasive-bladder-cancer-an-overview-on-drug-administration-technologies-and-pharmacokinetics
#10
Fabio Campodonico, Savino Di Stasi, Gad M Lev, Carlo Terrone, Luca Bongiovanni, Francesca Mattioli, Vincenzo Pagliarulo, Carlo Introini
BACKGROUND: Tumor recurrence is the most expected clinical event after the resection of non-muscle invasive bladder cancer, depending on histological findings of the initial lesion. In patients with low and intermediate risk of disease, the intravesical instillation of chemotherapy agents is recommended as a standard treatment to reduce recurrences. METHODS: A comprehensive review covering various aspects of different treatments with intravesical drugs is presented...
April 26, 2017: Current Drug Metabolism
https://www.readbyqxmd.com/read/28455657/-prostate-artery-embolization-pae-technique-and-results
#11
A Kovács
CLINICAL/METHODICAL ISSUE: In the treatment of the benign prostatic hyperplasia (BPH) medical and surgical therapies have been established. STANDARD RADIOLOGICAL METHODS: Prostate artery embolization (PAE) is an innovative endovascular technique that might close the gap between both these procedures. PERFORMANCE: The PAE procedure is safe and has a low incidence of side effects. The efficacy of PAE has been proven for medium sized and large sized glands as well as for intravesical protrusions...
April 28, 2017: Der Radiologe
https://www.readbyqxmd.com/read/28446032/effect-of-intravesical-liposome-based-nerve-growth-factor-antisense-therapy-on-bladder-overactivity-and-nociception-in-a-rat-model-of-cystitis-induced-by-hydrogen-peroxide
#12
Tsuyoshi Majima, Pradeep Tyagi, Koji Dogishi, Mahendra Kashyap, Yasuhito Funahashi, Momokazu Gotoh, Michael B Chancellor, Naoki Yoshimura
The aim of this study was to evaluate whether liposome-based local suppression of nerve growth factor (NGF) in the bladder has effects on bladder hypersensitivity in a rat cystitis model induced by intravesical instillation of hydrogen peroxide (HP). HP (1.5%) was intravesically administered to adult female Sprague-Dawley rats. Liposomes complexed with NGF antisense oligonucleotide (OND) labeled with TYE563 fluorescent tag were intravesically instilled on day 2. Red fluorescence from the TYE 563 tag was observed with fluorescent microscopy on day 3...
April 18, 2017: Human Gene Therapy
https://www.readbyqxmd.com/read/28423681/sulforaphane-for-the-chemoprevention-of-bladder-cancer-molecular-mechanism-targeted-approach
#13
REVIEW
Andrew Leone, Gregory Diorio, Wade Sexton, Michael Schell, Mark Alexandrow, Jed W Fahey, Nagi B Kumar
The clinical course for both early and late stage Bladder Cancer (BC) continues to be characterized by significant patient burden due to numerous occurrences and recurrences requiring frequent surveillance strategies, intravesical drug therapies, and even more aggressive treatments in patients with locally advanced or metastatic disease. For these reasons, BC is also the most expensive cancer to treat. Fortunately, BC offers an excellent platform for chemoprevention interventions with potential to optimize the systemic and local exposure of promising agents to the bladder mucosa...
March 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28423552/enhanced-antitumor-effects-by-combining-an-il-12-anti-dna-fusion-protein-with-avelumab-an-anti-pd-l1-antibody
#14
Jonathan K Fallon, Amanda J Vandeveer, Jeffrey Schlom, John W Greiner
The combined therapeutic potential of an immunocytokine designed to deliver IL-12 to the necrotic regions of solid tumors with an anti-PD-L1 antibody that disrupts the immunosuppressive PD-1/PD-L1 axis yielded a combinatorial benefit in multiple murine tumor models. The murine version of the immunocytokine, NHS-muIL12, consists of an antibody (NHS76) recognizing DNA/DNA-histone complexes, fused with two molecules of murine IL-12 (NHS-muIL12). By its recognition of exposed DNA, NHS-muIL12 targets IL-12 to the necrotic portions of tumors; it has a longer plasma half-life and better antitumor efficacy against murine tumors than recombinant murine IL-12...
March 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28420564/prognostic-role-of-neutrophil-to-lymphocyte-ratio-in-primary-non-muscle-invasive-bladder-cancer
#15
David D'Andrea, Marco Moschini, Kilian Gust, Mohammad Abufaraj, Mehmet Özsoy, Romain Mathieu, Francesco Soria, Alberto Briganti, Morgan Rouprêt, Pierre I Karakiewicz, Shahrokh F Shariat
INTRODUCTION: The purpose of this study was to assess the role of pretreatment neutrophil-to-lymphocyte ratio (NLR) as a predictor of clinical outcomes in patients treated with transurethral resection (TURB) for primary non-muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: Data from 918 patients treated with TURB for primary NMIBC were retrospectively collected. NLR was evaluated as binary variable with the cut-point of 3 based on the visual best correlation of the receiver operating curve analyses focusing on disease recurrence...
March 27, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28406993/topical-and-systemic-immunoreaction-triggered-by-intravesical-chemotherapy-in-an-n-butyl-n-4-hydroxybutyl-nitorosamine-induced-bladder-cancer-mouse-model
#16
Shunta Hori, Makito Miyake, Yoshihiro Tatsumi, Sayuri Onishi, Yosuke Morizawa, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto
Intravesical bacillus Calmette-Guerin (BCG) treatment is the most common therapy to prevent progression and recurrence of non-muscle invasive bladder cancer (NMIBC). Although the immunoreaction elicited by BCG treatment is well documented, those induced by intravesical treatment with chemotherapeutic agents are much less known. We investigated the immunological profiles caused by mitomycin C, gemcitabine, adriamycin and docetaxel in the N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced orthotopic bladder cancer mouse model...
2017: PloS One
https://www.readbyqxmd.com/read/28406148/bladder-cancer
#17
REVIEW
Oner Sanli, Jakub Dobruch, Margaret A Knowles, Maximilian Burger, Mehrdad Alemozaffar, Matthew E Nielsen, Yair Lotan
Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after transurethral resection of bladder tumour (TURBT), which also serves as the first stage of treatment. Bladder cancer develops via two distinct pathways, giving rise to non-muscle-invasive papillary tumours and non-papillary (solid) muscle-invasive tumours...
April 13, 2017: Nature Reviews. Disease Primers
https://www.readbyqxmd.com/read/28405683/bladder-intracavitary-hyperthermic-perfusion-chemotherapy-for-the-prevention-of-recurrence-of-non-muscle-invasive-bladder-cancer-after-transurethral-resection
#18
Mingchen Ba, Shuzhong Cui, Bin Wang, Hui Long, Zhaofei Yan, Shuai Wang, Yinbing Wu, Yuanfeng Gong
Preventing the recurrence of non-muscle invasive bladder cancer (NMIBC) post-transurethral resection (TUR) remains challenging. The aim of the present study was to investigate the effectiveness and safety of bladder intracavitary hyperthermic perfusion chemotherapy (BHPC) for prevention of NMIBC recurrence post-TUR. Between December 2006 and December 2014, 53 patients with NMIBC who underwent TUR were randomly assigned to receive BHPC (BHPC group, 28 patients) or intravesical chemotherapy alone (chemotherapy group, 25 patients) at the Intracelom Hyperthermic Perfusion Therapy Center of Guangzhou Medical University Cancer Hospital (Guangzhou, China)...
May 2017: Oncology Reports
https://www.readbyqxmd.com/read/28389159/validation-of-the-ezrin-ck20-and-ki-67-as-potential-predictive-markers-for-bcg-instillation-therapy-of-non-muscle-invasive-bladder-cancer
#19
Per-Uno Malmström, Tammer Hemdan, Ulrika Segersten
OBJECTIVE: The aim of our study was to try to validate 3 promising predictive biomarkers in a database based on prospective trials comparing bacillus Calmette-Guerin (BCG) with mitomycin-C and a combination of epirubicin and interferon, respectively. BACKGROUND: The most common form of bladder cancer is non-muscle-invasive tumors treated initially with transurethral resection. Unfortunately more than half recur and some also progress. Consequently, an attempt to prevent poor outcome is frequently made by intravesical instillations either by chemo- or immunotherapy...
April 4, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28360951/intravesical-formalin-for-hemorrhagic-cystitis-a-contemporary-cohort
#20
Matthew J Ziegelmann, Stephen A Boorjian, Daniel D Joyce, Brian D Montgomery, Brian J Linder
INTRODUCTION: Hemorrhagic cystitis presents a difficult clinical challenge, yet data regarding treatment options is sparse. Here, we sought to evaluate outcomes of a contemporary cohort of patients treated with intravesical formalin for hemorrhagic cystitis. METHODS: We identified a retrospective cohort of eight patients managed with formalin for hemorrhagic cystitis from 2000-2014. All patients failed prior measures, including bladder irrigation, clot evacuation, and other intravesical agents...
March 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
keyword
keyword
21306
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"